{"ticker": {"uuid": "afbab136-a8f8-490a-ac16-a6c79cabd2f6", "symbol": "SGMT", "name": "Sagimet Biosciences Inc. Series A Common Stock", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPWVJJUG0xck9PbkRQOG1CRXVCenhaUDFlZnp3S21RbDdvaW5xRDlhOUxpVEl4a1dXczRPVDkzd05kTERNWlVvMENtX3lpOW91em5EMV9MMl9yTlVYYWNCWGtud0pldGk4SmRzTENkcXU2ZDJ2QkRwb3R2cjY0WERwM2l1ZEF5WC02UkVoT20ybzlveFVWcWQ4UXE2VW5sY200d3hYcmZzUXdaUDR6?oc=5", "source_name": "Market source", "published_at": "2026-07-15T15:42:57+00:00", "published_display": "15 Jul 2026 15:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sagimet Biosciences(SGMT) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgJBVV95cUxObEtpV0ZCZ0lXYlZOY0JHQmZ4NDlwek53UFR3TEM0RHlRQzJGWkM2aXhjdmFobmtpVUZpeHBKRXhuZUZuV3NCSG5OYUlvaHNQUlRQYkxrZ2pWQ09haFNocVk4OHdvMUpuMWEzcElhdW9Ja0oxSTJKVkF3ZzRQR2lwc1JFNXYtQjJuQjZwRU1DTkVuUVhjNFJpNEhWMlNieFpHTU9iUzVvMDU0YXAxOXR1cTBPR0o2YlFURzNCVGpvenlka21SZmFQano2ZVhqZUxlNDNMenJiVHNxX3RTQVNKMzM5c0lDTEhIdkpreURnN0FXaENSajRaZTIzU1BITGhuMm1LdHpFcXFzM1ZaM2paSGNCZVFsUExQbDlRYmRTcXNwdjV0akhUWGxWRHVKQkwyQVUwWC02eWxaOFJ2eUMzRS1aWExsUU1uT21Vc29B?oc=5", "source_name": "Moomoo", "published_at": "2026-07-06T23:44:27+00:00", "published_display": "06 Jul 2026 23:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Sagimet Biosciences Inc. Class A \u2013 SWB:0O2", "summary": "This article provides access to the \"Price to earnings forward\" financial metric for Sagimet Biosciences Inc. Class A (SWB:0O2) on the Stuttgart Stock Exchange, as tracked by TradingView. It highlights that the market was closed with no trades at the time of the data. The content", "url": "https://www.tradingview.com/symbols/SWB-0O2/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T09:10:51", "published_display": "04 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Added to Russell Indexes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/sagimet-biosciences-added-russell-indexes-190023014.html", "source_name": "MT Newswires", "published_at": "2026-06-29T19:00:23+00:00", "published_display": "29 Jun 2026 19:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/sagimet-biosciences-joins-russell-2000-110000502.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T11:00:00+00:00", "published_display": "29 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet lands in Russell indexes as acne drug trial looms", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPbWYyd1puUXY0ZUctdFowV3R4cUVWc0NXLWFfVW1kWUNWMHNPYWQ5dFBrZTFOM0IyY2pWbFhGU21maDVoVjZ0eTNNRUVLc1I5aUNrU3NqWnA4WVRTT1dpakZ1MVZyRWtQb3E1bTF0Ulp3d1pqREJHUUhBaFpYQU8zcG0xZG1jRFZ4TUZrdUltYlV3bGhBa3dtVjQ5bFplR3JiNlh4VkVPN1gzek5BbTlZaUlmSjM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Sagimet Biosciences Inc. Class A \u2013 LS:A3CPAM", "summary": "This article provides financial information for Sagimet Biosciences Inc. Class A (LS:A3CPAM), specifically focusing on its price-to-earnings forward metric. The data is sourced from ICE Data Services and FactSet, indicating market closure and current lack of trades.", "url": "https://www.tradingview.com/symbols/LS-A3CPAM/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:09:27", "published_display": "28 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A \u2013 LS:A3CPAM", "summary": "This article provides financial information for Sagimet Biosciences Inc. Class A (LS:A3CPAM), specifically focusing on its enterprise value to EBIT forward metric. The content highlights that the market for this stock is currently closed with no trades. It also details the variou", "url": "https://www.tradingview.com/symbols/LS-A3CPAM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:39:57", "published_display": "28 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Sagimet Biosciences Inc. Class A \u2013 LS:A3CPAM", "summary": "This page provides financial information for Sagimet Biosciences Inc. Class A (LS:A3CPAM), specifically focusing on its forward price to sales ratio. The content also briefly touches upon market data sources and copyright information.", "url": "https://www.tradingview.com/symbols/LS-A3CPAM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:09:26", "published_display": "27 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "0O2 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target and forecast for Sagimet Biosciences Inc. Class A (0O2) based on analyst opinions. It details maximum and minimum price estimates, past price performance, upcoming earnings reports, and financial metrics like revenue and net income. The articl", "url": "https://www.tradingview.com/symbols/SWB-0O2/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T16:40:57", "published_display": "26 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Inc. Class A Actuals & Estimates (NASDAQ:SGMT)", "summary": "This article provides an overview of Sagimet Biosciences Inc. (NASDAQ:SGMT) stock, including its current price, historical performance, analyst forecasts, and financial details. It covers key metrics like market capitalization, volatility, earnings reports, and revenue, alongside", "url": "https://www.tradingview.com/symbols/NASDAQ-SGMT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:40:43", "published_display": "26 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/sagimet-biosciences-announces-participation-upcoming-004900302.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T00:49:00+00:00", "published_display": "23 Jun 2026 00:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Announces Participation in Upcoming", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxQMld0Q0VzWWlUNWlmUXlVcDZ4MDJ5YXVGVTlsMW9GMzZaTVI5ZEFfY3NmRnZObzFrQTdmcWhGc0VyWmxsZ1BNNXY4cUVVTThSdkwzMC1RRzBEN2trUHZROXZ3cUo0SFVHbnYxUHBhYXRTbUpXcFZ6Z1NkZHhCT1BpOW85Ylh3R19RZFdpQnpjMFNlZjNEbEtGSFRleVVmY3BuUXJaT3BaQVNLek53WlpiVDk4aGc0VEw2VFlldXM0SXItTWliemY4bnhUcVdPVVZocXNvY2RjVUQ5Z3BQdUJycnN1blREbkZMQ3ZFX254Ui1pUTZtbk1xdjdvLW9EOVhnVm05WURYMU83MUJOcDlya2JOenI1UjZUNi0yaEJBU3hZM014SkN4OXdnNA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) director receives stock option grant for 39,567 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcC1JdGZpdmRZSmJoR1VZTUlVWldMaW5pVFBycTdGQy01TkgweWVLNm10UDEtS3JKck5ibUdaWjYzamJhSGNZc3NrWEZBM3p2ZEs1OWFRejRrTVFFNl9aVVVpMWRMUUczcEhobzY4ZTFOWGs0bHRVYTlYRzVTbmtZTE9xc1NCR1h6UFZ2WFlwWE9XaEUzS1lvUEdmYlBPWXR0Q0ItZFVQX25FUkVOU1ZENHAyRmpQV2E4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) director resigns as shareholders elect Board, ratify KPMG", "summary": "Sagimet Biosciences Inc. reported that director Tim Walbert resigned from its Board effective June 12, 2026, due to other commitments, with no disagreements cited. During their 2026 Annual Meeting, shareholders elected four Class III directors\u2014Jennifer Jarrett, Anne Phillips, M.D", "url": "https://www.stocktitan.net/sec-filings/SGMT/8-k-sagimet-biosciences-inc-reports-material-event-716412340c49.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:08:39", "published_display": "12 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Grants New Performance-Based Executive Equity Awards", "summary": "Sagimet Biosciences (SGMT) recently granted significant performance-based executive equity awards to its CEO, CFO, and Chief Legal and Administrative Officer. These awards, issued on May 28, 2026, include stock options vesting over 48 months and performance-based restricted stock", "url": "https://www.tipranks.com/news/company-announcements/sagimet-biosciences-grants-new-performance-based-executive-equity-awards", "source_name": "TipRanks", "published_at": "2026-06-04T19:10:25", "published_display": "04 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNQ1NRRFZQck5kcmpRanV0SmFUY084ZWVjNDlKb0VFZlFxQVBqZV9oM1lzeVlOcmtsYW1FcFROeXFCS29qWm5US0I1Y1RScUE4cWIxLXZTNkFRdFFUN21hSVppM0tiWkpxYUYzdHkxRmg1VFpReWJxTGhLTEdmbFhNTTYya0tWMUlQay1Fd01pZmp3NjRCak11c3E0UFNHZnc?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) CLO awarded 100,000 stock options at $7.27", "summary": "Sagimet Biosciences Inc. reported that its Chief Legal & Admin. Officer, Elizabeth Rozek, was granted 100,000 stock options. These options have an exercise price of $7.27 per share and an expiration date of May 27, 2036. The shares associated with these options will vest in 48 eq", "url": "https://www.stocktitan.net/sec-filings/SGMT/form-4-sagimet-biosciences-inc-insider-trading-activity-39e016329b78.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:40:06", "published_display": "02 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) CMO receives 35,000 stock options at $7.27 strike", "summary": "Sagimet Biosciences (SGMT) Chief Medical Officer, Andreas Grauer, was granted 35,000 stock options with an exercise price of $7.27 per share. These options will vest in 48 equal monthly installments starting May 28, 2026, contingent upon his continued service. Grauer now directly", "url": "https://www.stocktitan.net/sec-filings/SGMT/form-4-sagimet-biosciences-inc-insider-trading-activity-3c9fda89b015.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:40:06", "published_display": "02 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) grants CEO options on 300,000 shares", "summary": "Sagimet Biosciences Inc. (SGMT) reported that its President & CEO, David Happel, was granted stock options for 300,000 shares of Series A common stock. These options have an exercise price of $7.27 per share and will vest in 48 equal monthly installments starting May 28, 2026, co", "url": "https://www.stocktitan.net/sec-filings/SGMT/form-4-sagimet-biosciences-inc-insider-trading-activity-1920f2f2323b.html", "source_name": "Stock Titan", "published_at": "2026-06-02T19:40:49", "published_display": "02 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)", "summary": "This article summarizes analyst ratings for three healthcare companies: MannKind (MNKD), Biohaven Ltd. (BHVN), and Precision BioSciences (DTIL). MannKind received a \"Strong Buy\" consensus with Wedbush maintaining a \"Buy\" rating. Biohaven Ltd. has a \"Moderate Buy\" consensus, with ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MNKD/pressreleases/2202653/analysts-conflicted-on-these-healthcare-names-mannkind-mnkd-biohaven-ltd-bhvn-and-precision-biosciences-dtil/", "source_name": "The Globe and Mail", "published_at": "2026-05-30T04:39:04", "published_display": "30 May 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sagimet-biosciences-presents-two-posters-110000983.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:00:00+00:00", "published_display": "27 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNS21RNzViTWVXeHY5cHlQWHBoVE9KOGdDYTFaUjhCZXNUSEVoZFROV0kyVDRrSGRYRHd6M2I5UHU0UWdGcEZULWpRWFhUVDA0MWFTYWY1YWZHV1NXek9Dc3AtaDNPMnQ0em1LQ2RFbjZIeDNXZFQtNUw5TlgtNS1yTndDVHFGeVZ0V3VTanhfRmpnUmRvNVhTcmJFZHBuQ0hqT2pJ?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (ARMP), Palvella Therapeutics (PVLA) and MBX Biosciences, Inc. (MBX)", "summary": "Three analysts have provided bullish insights on healthcare companies Armata Pharmaceuticals (ARMP), Palvella Therapeutics (PVLA), and MBX Biosciences, Inc. (MBX). Armata Pharmaceuticals received a Buy rating with a $20.00 price target, Palvella Therapeutics also received a Buy r", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1814456/analysts-offer-insights-on-healthcare-companies-armata-pharmaceuticals-armp-palvella-therapeutics-pvla-and-mbx-biosciences-inc-mbx/", "source_name": "The Globe and Mail", "published_at": "2026-05-20T13:09:50", "published_display": "20 May 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (NASDAQ: SGMT) cuts R&D spend and raises $175M equity", "summary": "Sagimet Biosciences reported a reduced net loss of $10.7 million for Q1 2026, down from $18.2 million in Q1 2025, primarily due to a 54% decrease in R&D expenses as MASH work wound down and focus shifted to acne programs. The company bolstered its financial position by raising $1", "url": "https://www.stocktitan.net/sec-filings/SGMT/10-q-sagimet-biosciences-inc-quarterly-earnings-report-f2ef384f2e6d.html", "source_name": "Stock Titan", "published_at": "2026-05-16T00:39:49", "published_display": "16 May 2026 00:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) CMO receives 264,759 stock options at $6.44 strike", "summary": "Sagimet Biosciences' Chief Medical Officer, Andreas Grauer, was granted 264,759 stock options with an exercise price of $6.44 per share, expiring on April 19, 2036. The options will vest over time, with 25% vesting on April 20, 2027, and the remaining 75% in 36 equal monthly inst", "url": "https://www.stocktitan.net/sec-filings/SGMT/form-4-sagimet-biosciences-inc-insider-trading-activity-b15f5c59cd74.html", "source_name": "Stock Titan", "published_at": "2026-05-15T10:40:19", "published_display": "15 May 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat (NASDAQ:SGMT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOa3lSei0wMWRWb1lfam42QnpOQ0t2dXAtc3ZCVVRzTk5QTi10RkFPOEtfakc3dHJLenhWb004aDJSbGE2dGplUDZobVBlaDFqNGJzdnREcGpKS2N5VnRaeGw5UnNUWko5c21odzJCbjc3dFpKTjlvLXJUM0JodVA3NG9jaG1NajM1RE1qYzJZcjlmM0RvN05OVVVMLVMzZ3owWG5nT1Y3dXNfOEhyc3drSWJ3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ", "summary": "", "url": "https://finance.yahoo.com/news/sagimet-biosciences-participate-h-c-110000346.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T11:00:00+00:00", "published_display": "13 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxQVXVjNHF3enVuZWozMzVob2UyUzZnbjFTUXNBRk14YWc2N2dyYmFkOHd0RVRjSkJ4REc3Zk5sdnhRNWhrM0FpUERhWTdMU0hJemF4MWRfd0FUREJrNGdWb2w1bEFGbTItM2tIQlhJUXFpbmV3LUNjTU5POUJZWThTUUp4emRkSGwyaXVhZkZ4c0xUVzVGY0o5bXFiNV9UNGZIN0JYb2l2M2hSUi1uYzdWQjlwOERNY2tNYkJ6UktVa08tOEhNYXBGcWJsRHl0WGlUckNHSENGS2h3SGl5UXRZNTJpREFOVkFWN0JyTmJjUXRDaUpEUlBieXJOdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After 40-year wait, Sagimet backs Phase 3 test of new oral acne drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZXlvdWcxUjB2VXN0SXpGUHNqRFgzU2M0XzJ0Q2RfeDV6ZWNtOXR3WVJEaE5qWktNTmFNU1RrTHNPV1BxN2x6RVRmVksxek9UeHkzZnJjVW11T3A3cUFtLTdsNU16eW9YTDB1YkdHYTlXNUlJWDNoYU1tbFl1NUtQTVFXOWRUWVJwcG1aYVl6NVhYd2RZNHhTdF9oLV9JdWpQY01JUWFDa1Vfa094ZjNZSmo3WWFTYk83ZWRubDRlOFQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sagimet-biosciences-present-mechanism-action-110000967.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T11:00:00+00:00", "published_display": "11 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPeF9UQWdYZEk3NnRUeFd4YjRxRVFRZ1cyNWJPaUtFUXZkS0xwaXJaUjZFX2lEbVp4NU16bklQMTJ5eHZUc3lGNDZZbERVYVc3cTV6R2RvMk1fWnBadkcwNkg5WjAzSkQwNkVlc052WHllYkR5dUFZbEM5eVA4YkFhSHBYZ25HZHFxSWlad3RILVZmMkdod3ZzdVF3bXM5T3RF?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Sagimet Biosciences, Inc. Class A (SGMT)", "summary": "Two healthcare stocks, Intellia Therapeutics (NTLA) and Sagimet Biosciences, Inc. Class A (SGMT), have received bullish sentiments from analysts. Leerink Partners reiterated a Buy rating on Intellia Therapeutics with a $35.00 price target, while Wedbush analyst Yun Zhong maintain", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NTLA/pressreleases/1566883/analysts-are-bullish-on-top-healthcare-stocks-intellia-therapeutics-ntla-sagimet-biosciences-inc-class-a-sgmt/", "source_name": "The Globe and Mail", "published_at": "2026-05-02T10:09:25", "published_display": "02 May 2026 10:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK) and Crescent Biopharma (CBIO)", "summary": "This article summarizes recent analyst ratings for three healthcare companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK), and Crescent Biopharma (CBIO). Analysts from Guggenheim, Bank of America Securities, and Piper Sandler maintained Buy or Hold ratings and provided spec", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CYTK/pressreleases/1643692/analysts-offer-insights-on-healthcare-companies-mbx-biosciences-inc-mbx-cytokinetics-cytk-and-crescent-biopharma-cbio/", "source_name": "The Globe and Mail", "published_at": "2026-05-02T04:39:18", "published_display": "02 May 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Sagimet Biosciences (SGMT) Valuation After Acne Trial Plans And Equity Raise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Announces Major Equity Offering for Pipeline", "summary": "Sagimet Biosciences announced an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share, expected to yield $164.5 million in net proceeds. This capital infusion will fund a Phase 3 clinical trial of denifanstat in acne, advance TVB-3567,", "url": "https://www.tipranks.com/news/company-announcements/sagimet-biosciences-announces-major-equity-offering-for-pipeline", "source_name": "TipRanks", "published_at": "2026-04-28T11:39:52", "published_display": "28 Apr 2026 11:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months \u2013 What\u2019s Got Retail Buzzing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPSWRCWW44b0VtRVF6cXJFRVZGRW1hTndwQzNJbUUtZFVnN0Y4d0F3bEJ6OFNZYkFWMjdvRElqTllwX1hsVEVxVGo5OGxGMU9iU1ljNHlRTjh3S0MyWl9vMVJPOFNHVUgtV1ZXM3ZmZ1RCVFhDQWk5cGhsT2VrX2g3NEpzc2hnZTFfNDl6NUE3Y19KRzlSYmYtRXpMR01IZXV3ZUpaSWtrVFJOZjdSc3M3N0JNaENWSjFHX21JWkRRblVVaWlzNDlHVXR3?oc=5", "source_name": "Stocktwits", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet raises $175M, says cash now funds acne programs through 2028", "summary": "Sagimet Biosciences (Nasdaq: SGMT) priced an underwritten offering of 29,166,700 Series A common shares at $6.00 per share, resulting in gross proceeds of approximately $175.0 million. The company intends to use the net proceeds to fund a Phase 3 denifanstat acne trial, advance T", "url": "https://www.stocktitan.net/news/SGMT/sagimet-biosciences-announces-pricing-of-175-0-million-underwritten-aorr1mtnlwhy.html", "source_name": "Stock Titan", "published_at": "2026-04-28T03:39:31", "published_display": "28 Apr 2026 03:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Inc. Prices Underwritten Offering of 29.2 Million Shares at $6.00 Each, Expected to Raise $175 Million", "summary": "Sagimet Biosciences Inc. has announced the pricing of an underwritten offering of 29,166,700 shares of Series A common stock at $6.00 per share, aiming to raise approximately $175 million. The funds are earmarked for funding a Phase 3 clinical trial for denifanstat in acne, advan", "url": "https://www.quiverquant.com/news/Sagimet+Biosciences+Inc.+Prices+Underwritten+Offering+of+29.2+Million+Shares+at+$6.00+Each,+Expected+to+Raise+$175+Million", "source_name": "Quiver Quantitative", "published_at": "2026-04-27T11:20:00", "published_display": "27 Apr 2026 11:20", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans", "summary": "Sagimet Biosciences (NASDAQ:SGMT) saw its shares jump 30% after announcing plans for a Phase 3 clinical trial in the U.S. for its acne treatment, denifanstat, to commence in the second half of 2026. The company is prioritizing its dermatology portfolio, supported by positive Phas", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sagimet-biosciences-shares-jump-30-151300235.html", "source_name": "Market source", "published_at": "2026-04-27T11:13:00", "published_display": "27 Apr 2026 11:13", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Sagimet Biosciences Stock Is Soaring Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQeVRHVlpwOUROS1VyUHk2dENLQkFtd2kwbDZ1YlAxRVZNU3d0d3FrLWNwUlpKcGxrcjE3N25aQ3REOXR0Ui1KM0poa0NyLUhXOGpWWnBRd1FIWmxIRkNFTGlvbmc1THhuTHRVenVMV25ERXYtajVMUVVwSGhObWI1dVBNcDE0N0RTVF9IUUdWd0ZoNTg?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Sagimet turns to two-decade drug veteran after its medical chief retires", "summary": "Sagimet Biosciences (Nasdaq: SGMT) has appointed Andreas Grauer, MD, as its new Chief Medical Officer, effective April 20, 2026. Dr. Grauer brings over two decades of global clinical development experience, replacing Eduardo Bruno Martins, MD, DPhil, who has retired but will cont", "url": "https://www.stocktitan.net/news/SGMT/sagimet-biosciences-announces-appointment-of-andreas-grauer-md-as-opnw6zuxu9gx.html", "source_name": "Stock Titan", "published_at": "2026-04-24T03:39:32", "published_display": "24 Apr 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Here's Why We're Not Too Worried About Sagimet Biosciences' (NASDAQ:SGMT) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Analysts Remain Optimistic in Sagimet Biosciences (SGMT)\u2019s Outlook Following Q4 and Full-Year 2025 Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOMUlGWm15bUJnQkhBT1hhVHlYWnZzd09lcEFjQjN0V2hBRXd2bmJqMGlSb1RNRUx4T0lIc2xRSmNjZXN2cTk3Mzg1bTVESWlMZ0g0V3pvcnJxUENpZ1dYY1BQVDRpMGI4aGx3dFpFYnVpSXNmNC1SUW4yNnhPNlhHUndldUQwc01kc2J0YTgtaGxHRlNJZTVYY1VFdDRBUWFsY2p3M0JpS2hLeWJaN3Vydg?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxPWVJJUG0xck9PbkRQOG1CRXVCenhaUDFlZnp3S21RbDdvaW5xRDlhOUxpVEl4a1dXczRPVDkzd05kTERNWlVvMENtX3lpOW91em5EMV9MMl9yTlVYYWNCWGtud0pldGk4SmRzTENkcXU2ZDJ2QkRwb3R2cjY0WERwM2l1ZEF5WC02UkVoT20ybzlveFVWcWQ4UXE2VW5sY200d3hYcmZzUXdaUDR6?oc=5", "source_name": "Market source", "published_at": "2026-07-15T15:42:57+00:00", "published_display": "15 Jul 2026 15:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences(SGMT) Stock Options Chain | Quotes & News", "summary": "", "url": "https://news.google.com/rss/articles/CBMizgJBVV95cUxObEtpV0ZCZ0lXYlZOY0JHQmZ4NDlwek53UFR3TEM0RHlRQzJGWkM2aXhjdmFobmtpVUZpeHBKRXhuZUZuV3NCSG5OYUlvaHNQUlRQYkxrZ2pWQ09haFNocVk4OHdvMUpuMWEzcElhdW9Ja0oxSTJKVkF3ZzRQR2lwc1JFNXYtQjJuQjZwRU1DTkVuUVhjNFJpNEhWMlNieFpHTU9iUzVvMDU0YXAxOXR1cTBPR0o2YlFURzNCVGpvenlka21SZmFQano2ZVhqZUxlNDNMenJiVHNxX3RTQVNKMzM5c0lDTEhIdkpreURnN0FXaENSajRaZTIzU1BITGhuMm1LdHpFcXFzM1ZaM2paSGNCZVFsUExQbDlRYmRTcXNwdjV0akhUWGxWRHVKQkwyQVUwWC02eWxaOFJ2eUMzRS1aWExsUU1uT21Vc29B?oc=5", "source_name": "Moomoo", "published_at": "2026-07-06T23:44:27+00:00", "published_display": "06 Jul 2026 23:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Sagimet Biosciences Inc. Class A \u2013 SWB:0O2", "summary": "This article provides access to the \"Price to earnings forward\" financial metric for Sagimet Biosciences Inc. Class A (SWB:0O2) on the Stuttgart Stock Exchange, as tracked by TradingView. It highlights that the market was closed with no trades at the time of the data. The content", "url": "https://www.tradingview.com/symbols/SWB-0O2/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-04T09:10:51", "published_display": "04 Jul 2026 09:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Added to Russell Indexes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/sagimet-biosciences-added-russell-indexes-190023014.html", "source_name": "MT Newswires", "published_at": "2026-06-29T19:00:23+00:00", "published_display": "29 Jun 2026 19:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Joins the Russell 2000\u00ae and Russell 3000\u00ae Indexes", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/sagimet-biosciences-joins-russell-2000-110000502.html", "source_name": "GlobeNewswire", "published_at": "2026-06-29T11:00:00+00:00", "published_display": "29 Jun 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet lands in Russell indexes as acne drug trial looms", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxPbWYyd1puUXY0ZUctdFowV3R4cUVWc0NXLWFfVW1kWUNWMHNPYWQ5dFBrZTFOM0IyY2pWbFhGU21maDVoVjZ0eTNNRUVLc1I5aUNrU3NqWnA4WVRTT1dpakZ1MVZyRWtQb3E1bTF0Ulp3d1pqREJHUUhBaFpYQU8zcG0xZG1jRFZ4TUZrdUltYlV3bGhBa3dtVjQ5bFplR3JiNlh4VkVPN1gzek5BbTlZaUlmSjM?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-29T07:00:00+00:00", "published_display": "29 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Sagimet Biosciences Inc. Class A \u2013 LS:A3CPAM", "summary": "This article provides financial information for Sagimet Biosciences Inc. Class A (LS:A3CPAM), specifically focusing on its price-to-earnings forward metric. The data is sourced from ICE Data Services and FactSet, indicating market closure and current lack of trades.", "url": "https://www.tradingview.com/symbols/LS-A3CPAM/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:09:27", "published_display": "28 Jun 2026 21:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBIT forward of Sagimet Biosciences Inc. Class A \u2013 LS:A3CPAM", "summary": "This article provides financial information for Sagimet Biosciences Inc. Class A (LS:A3CPAM), specifically focusing on its enterprise value to EBIT forward metric. The content highlights that the market for this stock is currently closed with no trades. It also details the variou", "url": "https://www.tradingview.com/symbols/LS-A3CPAM/financials-statistics-and-ratios/enterprise-value-ebit-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T00:39:57", "published_display": "28 Jun 2026 00:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Sagimet Biosciences Inc. Class A \u2013 LS:A3CPAM", "summary": "This page provides financial information for Sagimet Biosciences Inc. Class A (LS:A3CPAM), specifically focusing on its forward price to sales ratio. The content also briefly touches upon market data sources and copyright information.", "url": "https://www.tradingview.com/symbols/LS-A3CPAM/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T10:09:26", "published_display": "27 Jun 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "0O2 Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a price target and forecast for Sagimet Biosciences Inc. Class A (0O2) based on analyst opinions. It details maximum and minimum price estimates, past price performance, upcoming earnings reports, and financial metrics like revenue and net income. The articl", "url": "https://www.tradingview.com/symbols/SWB-0O2/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T16:40:57", "published_display": "26 Jun 2026 16:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Inc. Class A Actuals & Estimates (NASDAQ:SGMT)", "summary": "This article provides an overview of Sagimet Biosciences Inc. (NASDAQ:SGMT) stock, including its current price, historical performance, analyst forecasts, and financial details. It covers key metrics like market capitalization, volatility, earnings reports, and revenue, alongside", "url": "https://www.tradingview.com/symbols/NASDAQ-SGMT/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T03:40:43", "published_display": "26 Jun 2026 03:40", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/healthcare/articles/sagimet-biosciences-announces-participation-upcoming-004900302.html", "source_name": "GlobeNewswire", "published_at": "2026-06-23T00:49:00+00:00", "published_display": "23 Jun 2026 00:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Announces Participation in Upcoming", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwJBVV95cUxQMld0Q0VzWWlUNWlmUXlVcDZ4MDJ5YXVGVTlsMW9GMzZaTVI5ZEFfY3NmRnZObzFrQTdmcWhGc0VyWmxsZ1BNNXY4cUVVTThSdkwzMC1RRzBEN2trUHZROXZ3cUo0SFVHbnYxUHBhYXRTbUpXcFZ6Z1NkZHhCT1BpOW85Ylh3R19RZFdpQnpjMFNlZjNEbEtGSFRleVVmY3BuUXJaT3BaQVNLek53WlpiVDk4aGc0VEw2VFlldXM0SXItTWliemY4bnhUcVdPVVZocXNvY2RjVUQ5Z3BQdUJycnN1blREbkZMQ3ZFX254Ui1pUTZtbk1xdjdvLW9EOVhnVm05WURYMU83MUJOcDlya2JOenI1UjZUNi0yaEJBU3hZM014SkN4OXdnNA?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-06-22T07:00:00+00:00", "published_display": "22 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) director receives stock option grant for 39,567 shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOcC1JdGZpdmRZSmJoR1VZTUlVWldMaW5pVFBycTdGQy01TkgweWVLNm10UDEtS3JKck5ibUdaWjYzamJhSGNZc3NrWEZBM3p2ZEs1OWFRejRrTVFFNl9aVVVpMWRMUUczcEhobzY4ZTFOWGs0bHRVYTlYRzVTbmtZTE9xc1NCR1h6UFZ2WFlwWE9XaEUzS1lvUEdmYlBPWXR0Q0ItZFVQX25FUkVOU1ZENHAyRmpQV2E4?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) director resigns as shareholders elect Board, ratify KPMG", "summary": "Sagimet Biosciences Inc. reported that director Tim Walbert resigned from its Board effective June 12, 2026, due to other commitments, with no disagreements cited. During their 2026 Annual Meeting, shareholders elected four Class III directors\u2014Jennifer Jarrett, Anne Phillips, M.D", "url": "https://www.stocktitan.net/sec-filings/SGMT/8-k-sagimet-biosciences-inc-reports-material-event-716412340c49.html", "source_name": "Stock Titan", "published_at": "2026-06-12T20:08:39", "published_display": "12 Jun 2026 20:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxQM0ExNm9zZVBVMzB2cTFsYkhQeDJyeUV5Y1lSdWdsa2V2STFTSFBkYVlrRDJaUmE0bjZVLUxmZEh1UkFPbndtdWVDWmJBcEJaSmpTSlN4RkFkdF9EYkhFUXh3YWxqREkxRllfRXE0bFVuSkMwaExFNmk0UmNoa2R2NmQyb0p1N2pudENMMGMwWmVGT0J5SUxfeE5hT2hpUms1NHR4NzY1VWpNQVFYUWJkUnN3?oc=5", "source_name": "TradingView", "published_at": "2026-06-11T07:00:00+00:00", "published_display": "11 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Grants New Performance-Based Executive Equity Awards", "summary": "Sagimet Biosciences (SGMT) recently granted significant performance-based executive equity awards to its CEO, CFO, and Chief Legal and Administrative Officer. These awards, issued on May 28, 2026, include stock options vesting over 48 months and performance-based restricted stock", "url": "https://www.tipranks.com/news/company-announcements/sagimet-biosciences-grants-new-performance-based-executive-equity-awards", "source_name": "TipRanks", "published_at": "2026-06-04T19:10:25", "published_display": "04 Jun 2026 19:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNQ1NRRFZQck5kcmpRanV0SmFUY084ZWVjNDlKb0VFZlFxQVBqZV9oM1lzeVlOcmtsYW1FcFROeXFCS29qWm5US0I1Y1RScUE4cWIxLXZTNkFRdFFUN21hSVppM0tiWkpxYUYzdHkxRmg1VFpReWJxTGhLTEdmbFhNTTYya0tWMUlQay1Fd01pZmp3NjRCak11c3E0UFNHZnc?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) CLO awarded 100,000 stock options at $7.27", "summary": "Sagimet Biosciences Inc. reported that its Chief Legal & Admin. Officer, Elizabeth Rozek, was granted 100,000 stock options. These options have an exercise price of $7.27 per share and an expiration date of May 27, 2036. The shares associated with these options will vest in 48 eq", "url": "https://www.stocktitan.net/sec-filings/SGMT/form-4-sagimet-biosciences-inc-insider-trading-activity-39e016329b78.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:40:06", "published_display": "02 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) CMO receives 35,000 stock options at $7.27 strike", "summary": "Sagimet Biosciences (SGMT) Chief Medical Officer, Andreas Grauer, was granted 35,000 stock options with an exercise price of $7.27 per share. These options will vest in 48 equal monthly installments starting May 28, 2026, contingent upon his continued service. Grauer now directly", "url": "https://www.stocktitan.net/sec-filings/SGMT/form-4-sagimet-biosciences-inc-insider-trading-activity-3c9fda89b015.html", "source_name": "Stock Titan", "published_at": "2026-06-02T20:40:06", "published_display": "02 Jun 2026 20:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) grants CEO options on 300,000 shares", "summary": "Sagimet Biosciences Inc. (SGMT) reported that its President & CEO, David Happel, was granted stock options for 300,000 shares of Series A common stock. These options have an exercise price of $7.27 per share and will vest in 48 equal monthly installments starting May 28, 2026, co", "url": "https://www.stocktitan.net/sec-filings/SGMT/form-4-sagimet-biosciences-inc-insider-trading-activity-1920f2f2323b.html", "source_name": "Stock Titan", "published_at": "2026-06-02T19:40:49", "published_display": "02 Jun 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Conflicted on These Healthcare Names: MannKind (MNKD), Biohaven Ltd. (BHVN) and Precision BioSciences (DTIL)", "summary": "This article summarizes analyst ratings for three healthcare companies: MannKind (MNKD), Biohaven Ltd. (BHVN), and Precision BioSciences (DTIL). MannKind received a \"Strong Buy\" consensus with Wedbush maintaining a \"Buy\" rating. Biohaven Ltd. has a \"Moderate Buy\" consensus, with ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/MNKD/pressreleases/2202653/analysts-conflicted-on-these-healthcare-names-mannkind-mnkd-biohaven-ltd-bhvn-and-precision-biosciences-dtil/", "source_name": "The Globe and Mail", "published_at": "2026-05-30T04:39:04", "published_display": "30 May 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Presents Two Posters at EASL 2026 on Denifanstat/Resmetirom Combination in MASH", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sagimet-biosciences-presents-two-posters-110000983.html", "source_name": "GlobeNewswire", "published_at": "2026-05-27T11:00:00+00:00", "published_display": "27 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UNH stock jumps on Q1 earnings beat and raised guidance to $18.25+", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPTEprdzNMNGZxdkg5Wll5MTlvS1dheXQybm14TERTcGVzcHQzY0llOEpTa0dpZ1hGdHVyNWZ2cFFiWmZRdkl1aUp4YVlTMVJxSDRzaEdzRFB1cW93QzdhSmNxcEZDMWhGX2F0ODJFcjY1Mk1kMVhLNnVJSUhVMHZpRjRtTHo2cXBvbVJ3a05SWlJNMUdrSzFPbA?oc=5", "source_name": "eciks.org", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 84, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxNS21RNzViTWVXeHY5cHlQWHBoVE9KOGdDYTFaUjhCZXNUSEVoZFROV0kyVDRrSGRYRHd6M2I5UHU0UWdGcEZULWpRWFhUVDA0MWFTYWY1YWZHV1NXek9Dc3AtaDNPMnQ0em1LQ2RFbjZIeDNXZFQtNUw5TlgtNS1yTndDVHFGeVZ0V3VTanhfRmpnUmRvNVhTcmJFZHBuQ0hqT2pJ?oc=5", "source_name": "Market source", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: Armata Pharmaceuticals (ARMP), Palvella Therapeutics (PVLA) and MBX Biosciences, Inc. (MBX)", "summary": "Three analysts have provided bullish insights on healthcare companies Armata Pharmaceuticals (ARMP), Palvella Therapeutics (PVLA), and MBX Biosciences, Inc. (MBX). Armata Pharmaceuticals received a Buy rating with a $20.00 price target, Palvella Therapeutics also received a Buy r", "url": "https://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/1814456/analysts-offer-insights-on-healthcare-companies-armata-pharmaceuticals-armp-palvella-therapeutics-pvla-and-mbx-biosciences-inc-mbx/", "source_name": "The Globe and Mail", "published_at": "2026-05-20T13:09:50", "published_display": "20 May 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (NASDAQ: SGMT) cuts R&D spend and raises $175M equity", "summary": "Sagimet Biosciences reported a reduced net loss of $10.7 million for Q1 2026, down from $18.2 million in Q1 2025, primarily due to a 54% decrease in R&D expenses as MASH work wound down and focus shifted to acne programs. The company bolstered its financial position by raising $1", "url": "https://www.stocktitan.net/sec-filings/SGMT/10-q-sagimet-biosciences-inc-quarterly-earnings-report-f2ef384f2e6d.html", "source_name": "Stock Titan", "published_at": "2026-05-16T00:39:49", "published_display": "16 May 2026 00:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences (SGMT) CMO receives 264,759 stock options at $6.44 strike", "summary": "Sagimet Biosciences' Chief Medical Officer, Andreas Grauer, was granted 264,759 stock options with an exercise price of $6.44 per share, expiring on April 19, 2036. The options will vest over time, with 25% vesting on April 20, 2027, and the remaining 75% in 36 equal monthly inst", "url": "https://www.stocktitan.net/sec-filings/SGMT/form-4-sagimet-biosciences-inc-insider-trading-activity-b15f5c59cd74.html", "source_name": "Stock Titan", "published_at": "2026-05-15T10:40:19", "published_display": "15 May 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences: Making The Bull Case For Differentiated Denifanstat (NASDAQ:SGMT)", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxOa3lSei0wMWRWb1lfam42QnpOQ0t2dXAtc3ZCVVRzTk5QTi10RkFPOEtfakc3dHJLenhWb004aDJSbGE2dGplUDZobVBlaDFqNGJzdnREcGpKS2N5VnRaeGw5UnNUWko5c21odzJCbjc3dFpKTjlvLXJUM0JodVA3NG9jaG1NajM1RE1qYzJZcjlmM0RvN05OVVVMLVMzZ3owWG5nT1Y3dXNfOEhyc3drSWJ3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ", "summary": "", "url": "https://finance.yahoo.com/news/sagimet-biosciences-participate-h-c-110000346.html", "source_name": "GlobeNewswire", "published_at": "2026-05-13T11:00:00+00:00", "published_display": "13 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "PDS BIOTECHNOLOGY ($PDSB) Releases Q1 2026 Earnings | PDSB Stock News", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxOcEdqLWM1SmVuNHpvZ2poNU5mOFppaWNtUi1IQVRHTmgxLUpyZHdUSDRnekdzMmVFQzFzUGo2RjlYenpCaTlfcUZhMm1yTzRwWUxnM01WY0libmxIVXNSM3RtMGxMY2RURTdMVW96bGU0SGZXRkE2SnVQdVNNUWw5RWtJQVJMX2pQQnRBRHBKMlRCUDct?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-13T07:00:00+00:00", "published_display": "13 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-wFBVV95cUxQVXVjNHF3enVuZWozMzVob2UyUzZnbjFTUXNBRk14YWc2N2dyYmFkOHd0RVRjSkJ4REc3Zk5sdnhRNWhrM0FpUERhWTdMU0hJemF4MWRfd0FUREJrNGdWb2w1bEFGbTItM2tIQlhJUXFpbmV3LUNjTU5POUJZWThTUUp4emRkSGwyaXVhZkZ4c0xUVzVGY0o5bXFiNV9UNGZIN0JYb2l2M2hSUi1uYzdWQjlwOERNY2tNYkJ6UktVa08tOEhNYXBGcWJsRHl0WGlUckNHSENGS2h3SGl5UXRZNTJpREFOVkFWN0JyTmJjUXRDaUpEUlBieXJOdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "After 40-year wait, Sagimet backs Phase 3 test of new oral acne drug", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwAFBVV95cUxNZXlvdWcxUjB2VXN0SXpGUHNqRFgzU2M0XzJ0Q2RfeDV6ZWNtOXR3WVJEaE5qWktNTmFNU1RrTHNPV1BxN2x6RVRmVksxek9UeHkzZnJjVW11T3A3cUFtLTdsNU16eW9YTDB1YkdHYTlXNUlJWDNoYU1tbFl1NUtQTVFXOWRUWVJwcG1aYVl6NVhYd2RZNHhTdF9oLV9JdWpQY01JUWFDa1Vfa094ZjNZSmo3WWFTYk83ZWRubDRlOFQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-12T07:00:00+00:00", "published_display": "12 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sagimet-biosciences-present-mechanism-action-110000967.html", "source_name": "GlobeNewswire", "published_at": "2026-05-11T11:00:00+00:00", "published_display": "11 May 2026 11:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxPeF9UQWdYZEk3NnRUeFd4YjRxRVFRZ1cyNWJPaUtFUXZkS0xwaXJaUjZFX2lEbVp4NU16bklQMTJ5eHZUc3lGNDZZbERVYVc3cTV6R2RvMk1fWnBadkcwNkg5WjAzSkQwNkVlc052WHllYkR5dUFZbEM5eVA4YkFhSHBYZ25HZHFxSWlad3RILVZmMkdod3ZzdVF3bXM5T3RF?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Are Bullish on Top Healthcare Stocks: Intellia Therapeutics (NTLA), Sagimet Biosciences, Inc. Class A (SGMT)", "summary": "Two healthcare stocks, Intellia Therapeutics (NTLA) and Sagimet Biosciences, Inc. Class A (SGMT), have received bullish sentiments from analysts. Leerink Partners reiterated a Buy rating on Intellia Therapeutics with a $35.00 price target, while Wedbush analyst Yun Zhong maintain", "url": "https://www.theglobeandmail.com/investing/markets/stocks/NTLA/pressreleases/1566883/analysts-are-bullish-on-top-healthcare-stocks-intellia-therapeutics-ntla-sagimet-biosciences-inc-class-a-sgmt/", "source_name": "The Globe and Mail", "published_at": "2026-05-02T10:09:25", "published_display": "02 May 2026 10:09", "sentiment": "positive", "sentiment_pct": 73, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK) and Crescent Biopharma (CBIO)", "summary": "This article summarizes recent analyst ratings for three healthcare companies: MBX Biosciences, Inc. (MBX), Cytokinetics (CYTK), and Crescent Biopharma (CBIO). Analysts from Guggenheim, Bank of America Securities, and Piper Sandler maintained Buy or Hold ratings and provided spec", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CYTK/pressreleases/1643692/analysts-offer-insights-on-healthcare-companies-mbx-biosciences-inc-mbx-cytokinetics-cytk-and-crescent-biopharma-cbio/", "source_name": "The Globe and Mail", "published_at": "2026-05-02T04:39:18", "published_display": "02 May 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look At Sagimet Biosciences (SGMT) Valuation After Acne Trial Plans And Equity Raise", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-01T07:00:00+00:00", "published_display": "01 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "GE HealthCare (NASDAQ:GEHC) Posts Better-Than-Expected Sales In Q1 CY2026 But Stock Drops", "summary": "", "url": "https://news.google.com/rss/articles/CBMi3gFBVV95cUxOUjRRb0hlcHlOazlmelFaVVJSQWNnRmExZVBEQW1HMmVLTjNyU3d4WElsU05hdGlfYWFSY0twMTNWOVVCY0h4U2dYQ19BQl9pa3o0NWNBLW50WmFsSEVHdmJFV3JabnN5MFZpUWZabjZzY2tjMUtxbndONm9DS3NxTUp3Qjg2dWZnMDR2NXZ2eU80MWhSODVKdVgxZVJ6TWs3RFpCaDFqMXVtVkhmRVlOcWtqYUV1X1FPcGpfdERhRmwzdkZDaWxtSnJnd25Oam4yTnFHTFBkZi0tM1BZdkE?oc=5", "source_name": "StockStory", "published_at": "2026-04-29T07:00:00+00:00", "published_display": "29 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Announces Major Equity Offering for Pipeline", "summary": "Sagimet Biosciences announced an underwritten public offering of 29,166,700 shares of its Series A common stock at $6.00 per share, expected to yield $164.5 million in net proceeds. This capital infusion will fund a Phase 3 clinical trial of denifanstat in acne, advance TVB-3567,", "url": "https://www.tipranks.com/news/company-announcements/sagimet-biosciences-announces-major-equity-offering-for-pipeline", "source_name": "TipRanks", "published_at": "2026-04-28T11:39:52", "published_display": "28 Apr 2026 11:39", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "SGMT Stock Surged 40% And Breached 200-DMA For The First Time In Nearly 3 Months \u2013 What\u2019s Got Retail Buzzing?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxPSWRCWW44b0VtRVF6cXJFRVZGRW1hTndwQzNJbUUtZFVnN0Y4d0F3bEJ6OFNZYkFWMjdvRElqTllwX1hsVEVxVGo5OGxGMU9iU1ljNHlRTjh3S0MyWl9vMVJPOFNHVUgtV1ZXM3ZmZ1RCVFhDQWk5cGhsT2VrX2g3NEpzc2hnZTFfNDl6NUE3Y19KRzlSYmYtRXpMR01IZXV3ZUpaSWtrVFJOZjdSc3M3N0JNaENWSjFHX21JWkRRblVVaWlzNDlHVXR3?oc=5", "source_name": "Stocktwits", "published_at": "2026-04-28T07:00:00+00:00", "published_display": "28 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet raises $175M, says cash now funds acne programs through 2028", "summary": "Sagimet Biosciences (Nasdaq: SGMT) priced an underwritten offering of 29,166,700 Series A common shares at $6.00 per share, resulting in gross proceeds of approximately $175.0 million. The company intends to use the net proceeds to fund a Phase 3 denifanstat acne trial, advance T", "url": "https://www.stocktitan.net/news/SGMT/sagimet-biosciences-announces-pricing-of-175-0-million-underwritten-aorr1mtnlwhy.html", "source_name": "Stock Titan", "published_at": "2026-04-28T03:39:31", "published_display": "28 Apr 2026 03:39", "sentiment": "positive", "sentiment_pct": 66, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Inc. Prices Underwritten Offering of 29.2 Million Shares at $6.00 Each, Expected to Raise $175 Million", "summary": "Sagimet Biosciences Inc. has announced the pricing of an underwritten offering of 29,166,700 shares of Series A common stock at $6.00 per share, aiming to raise approximately $175 million. The funds are earmarked for funding a Phase 3 clinical trial for denifanstat in acne, advan", "url": "https://www.quiverquant.com/news/Sagimet+Biosciences+Inc.+Prices+Underwritten+Offering+of+29.2+Million+Shares+at+$6.00+Each,+Expected+to+Raise+$175+Million", "source_name": "Quiver Quantitative", "published_at": "2026-04-27T11:20:00", "published_display": "27 Apr 2026 11:20", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet Biosciences Shares Jump 30% on Acne Trial Expansion Plans", "summary": "Sagimet Biosciences (NASDAQ:SGMT) saw its shares jump 30% after announcing plans for a Phase 3 clinical trial in the U.S. for its acne treatment, denifanstat, to commence in the second half of 2026. The company is prioritizing its dermatology portfolio, supported by positive Phas", "url": "https://finance.yahoo.com/sectors/healthcare/articles/sagimet-biosciences-shares-jump-30-151300235.html", "source_name": "Market source", "published_at": "2026-04-27T11:13:00", "published_display": "27 Apr 2026 11:13", "sentiment": "positive", "sentiment_pct": 80, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Sagimet Biosciences Stock Is Soaring Today", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxQeVRHVlpwOUROS1VyUHk2dENLQkFtd2kwbDZ1YlAxRVZNU3d0d3FrLWNwUlpKcGxrcjE3N25aQ3REOXR0Ui1KM0poa0NyLUhXOGpWWnBRd1FIWmxIRkNFTGlvbmc1THhuTHRVenVMV25ERXYtajVMUVVwSGhObWI1dVBNcDE0N0RTVF9IUUdWd0ZoNTg?oc=5", "source_name": "The Motley Fool", "published_at": "2026-04-27T07:00:00+00:00", "published_display": "27 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Sagimet turns to two-decade drug veteran after its medical chief retires", "summary": "Sagimet Biosciences (Nasdaq: SGMT) has appointed Andreas Grauer, MD, as its new Chief Medical Officer, effective April 20, 2026. Dr. Grauer brings over two decades of global clinical development experience, replacing Eduardo Bruno Martins, MD, DPhil, who has retired but will cont", "url": "https://www.stocktitan.net/news/SGMT/sagimet-biosciences-announces-appointment-of-andreas-grauer-md-as-opnw6zuxu9gx.html", "source_name": "Stock Titan", "published_at": "2026-04-24T03:39:32", "published_display": "24 Apr 2026 03:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Abbott is the most oversold healthcare stock as Q1 earnings roll on (XLV:NYSEARCA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOc2thQjFpazgwaFRfS3NjVXhlTkdFWHNFb240S0Z6akFtQXFIMmFmaXZnQ1A3OFVCQW9DT25OLVBQdGN5Yk52Mk9yUFlSX19ZS3FRTjZoR05zc2FVc25pVHQ0TDVHT2JmVnJabGNCREdLT2stV0IzLVdHWXpFZGU3V1NnVGhYbFRzNURVek41TVRmLWZQZTFYUkc4aXM0a1cwTkNFYTBfVnQ?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why We're Not Too Worried About Sagimet Biosciences' (NASDAQ:SGMT) Cash Burn Situation", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-18T07:00:00+00:00", "published_display": "18 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Analysts Remain Optimistic in Sagimet Biosciences (SGMT)\u2019s Outlook Following Q4 and Full-Year 2025 Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMisAFBVV95cUxOMUlGWm15bUJnQkhBT1hhVHlYWnZzd09lcEFjQjN0V2hBRXd2bmJqMGlSb1RNRUx4T0lIc2xRSmNjZXN2cTk3Mzg1bTVESWlMZ0g0V3pvcnJxUENpZ1dYY1BQVDRpMGI4aGx3dFpFYnVpSXNmNC1SUW4yNnhPNlhHUndldUQwc01kc2J0YTgtaGxHRlNJZTVYY1VFdDRBUWFsY2p3M0JpS2hLeWJaN3Vydg?oc=5", "source_name": "Market source", "published_at": "2026-03-25T07:00:00+00:00", "published_display": "25 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology Stock Declines More Than 9% in a Month: Here's Why", "summary": "", "url": "https://news.google.com/rss/articles/CBMijAFBVV95cUxNTTJZRVF4TFNBb3BhMW9VUnBnMVZhenZLNlZJY3Ryc3pGZ3dhZXBDY3pId0I5NFdmVTdiR2EyNXNBZFFuQ1M2M3pUTlRZdXJkbGxaT29mWm4wTG5fU2RtV1hIZWRwZUVNb3BEbTZKX3NPRV9mZVpiY3JBZDdMSDRveW1Jb0lIVmRKLVlidA?oc=5", "source_name": "Market source", "published_at": "2026-03-18T07:00:00+00:00", "published_display": "18 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did Puma Biotechnology's Stock Plummet Despite Beating Q4 Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxQUEQ4TXY0R1lWMTJIcEJySm5iaEl1UkJ6TDMxcUtQYVl3UmxYdlJnaElpdlJDLU0xTTRvT0dsellqX21Tc3lxWW9IbWxHMnFBZGlxajdnUUU2OTNVY0l3NUh0OExMUENwWGxqY1d5dXV3YmRDZm9IRzc1c3FjbUh2cGxvdEJMZ25lYXdjSUliZ0txSjVFOHJhUXNTajBLeVV0M3B4dDk4V3dfQQ?oc=5", "source_name": "Kavout | AI", "published_at": "2026-02-28T09:53:07+00:00", "published_display": "28 Feb 2026 09:53", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cava Stock Surges 24% After Upbeat Earnings and Strong 2026 Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxQcV9JR0t0QUpQRWhQU0JxOGZld2wxZmNTb0ZoV05TZVBhUjRxRGF2Zno5YWRaVkxKRzNsbk8yY01fdk95S09xcV9aT0FFS1A3Zzhfd0ZLVVVRVU1jY1BiZmZ6T0drMjlfLVNXMTVBZjdtWXdNTEdHTEc2ejFqX1lTREs3eXBhbWRjaUhRWHJMZlYxWGFGZnYwOUJ2Mm9uQQ?oc=5", "source_name": "TIKR.com", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 67, "sentiment_summary": {"positive": 14, "negative": 2, "neutral": 51, "score": 54, "total": 67, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 82, "events": [{"event": "general", "label": "Market update", "weight": 23.25, "count": 41}, {"event": "earnings", "label": "Earnings", "weight": 10.74, "count": 20}, {"event": "analyst", "label": "Analyst action", "weight": 2.2, "count": 4}, {"event": "liquidity", "label": "Balance sheet", "weight": 1.1, "count": 2}], "positive_events": 14, "negative_events": 2}, "market_context": {"has_market_context": true, "latest_close": 7.37, "latest_week": "2026-07-10", "one_week_move": -3.2, "four_week_move": 13.7, "twelve_week_move": 13.9, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.783588, "market_dynamics_buy_signal": false, "relative_strength": -7.548531, "fair_value_gap": 22.7, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 52.234, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-3.2% over one week, +13.7% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 64, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 12}, {"label": "Stock Titan", "count": 11}, {"label": "TradingView", "count": 8}, {"label": "GlobeNewswire", "count": 7}, {"label": "The Globe and Mail", "count": 4}, {"label": "simplywall.st", "count": 4}, {"label": "TipRanks", "count": 2}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 60}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 41}, {"label": "Earnings", "count": 20}, {"label": "Analyst action", "count": 4}, {"label": "Balance sheet", "count": 2}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "82/100 classification confidence."}, {"label": "Company focus", "value": "60", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "4", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-3.2% over one week, +13.7% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Sagimet Biosciences (SGMT) Attracts Attention After Russel Indexes Inclusion"}], "updated_at": "2026-07-16T11:42:19.920056+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}